Skip to main content
Premium Trial:

Request an Annual Quote

FedMed to Cover BioTheranostics Cancer MDx Tests

NEW YORK (GenomeWeb) – Genomic cancer diagnostic firm BioTheranostics today announced a contract with preferred provider organization FedMed to cover its tests for breast cancer and metastatic cancers.

As a result of the agreement, FedMed's 40 million covered lives will have access to San Diego-based BioTheranostics tests, including the Breast Cancer Index, which quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer, as well as the BioT3 Metastatic Cancer Solution suite of tests, which provides diagnostic and therapeutic information for metastatic cancer patients.

The BioT3 Metastatic Cancer Solution tests include the CancerType ID molecular classifier for diagnosing tumor type and subtype, and the CancerTreatment ID, which uses next-generation sequencing and predictive biomarkers to identify appropriate treatment options.

Today's announcement is the latest in a string of agreements that BioTheranostics has recently reached with PPOs, including Prime Health Services and Three Rivers Provider Network.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.